Neoadjuvant chemotherapy in "technically" inoperable locally advanced oesophageal (O) and gastro-oesophageal junction (GOJ) cancer.
K. Cheong,K. Chrystal,M. Forshaw,J. Gossage,E. Galani,A. Botha,R. Mason,P. Harper
DOI: https://doi.org/10.1200/jco.2004.22.90140.4138
IF: 45.3
2004-07-15
Journal of Clinical Oncology
Abstract:4138 Background: Primary surgery results in a poor outcome for patients with locally advanced O and GOJ tumours who at staging have no distant metastases. For this group we routinely use 3 cycles of neoadjuvant ECF-based chemotherapy (Epirubicin:60mg/m2, Cisplatin:60mg/m2, 5FU 200mg/m2 CIVI q21). Following full restaging, surgical resection is offered if adequate clinical and radiological response. Methods We retrospectively reviewed the outcome of 236pts referred for consideration of surgery between Aug 1999- Jan 2003. Of these, 71 were considered initially inoperable, locally advanced with no distant metastasis. All patients commencing chemotherapy were included. Chemotherapy variations depended on comorbidities and renal function.
RESULTS
Median age: 62yrs, 86% males.
HISTOLOGY
adenocarcinoma 80%, squamous cell 20%. Tumour Location: GO junction 76%, oesophageal 24%. Stage at presentation: T3/T4N0 17%, T3/T4N1 58%, and T3/T4N1M1a 25%. Chemotherapy regimen: ECF 73%, ECSF 10%, ECarboF 10%, CF 7%. 85% of patients completed a minimum of 3 cycles of neoadjuvant chemotherapy. Grade 3/4 toxicities: neutropenia 34%, febrile neutropenia 8%, nausea/vomiting 8%, diarrhoea 5%, cardiovascular 5%, neuropathy 2%. The overall radiological response rate was 49% (7%CR and 42%PR) 36% SD and 15% PD. 42 pts (59%) proceeded to surgery. 5 were unresectable. 45% were pathologically downstaged with 4pts (9.5%) achieving a pCR. 18 pts had further adjuvant therapy (34% chemo, 7% chemoradiation, 2% radiation). Median F/U was 18mths (1-49) Median overall survival (mOS) for the whole group was 12.1 mth with 1yr and 2yr OS of 52% and 28% respectively. For the pts undergoing surgery the mOS was 23.8 mths and 1 and 2yr OS 69% and 45%. 8 pts are currently alive without disease at 3 years. Patients not proceeding to surgery had a mOS of 9.9 mths.
CONCLUSIONS
Surgery following successful neoadjuvant chemotherapy for initially inoperable locally advanced O and GOJ cancer can produce encouraging survival rates. Prospective studies, including identification of prognostic and predictive factors for response to chemotherapy are required. No significant financial relationships to disclose.